Form D · Biotechnology
QMatter, Inc.
London, X0 · CIK 0002128509
Offering snapshot reported Apr 9, 2026 · SEC filing
- Reported sold
- $1.18M Offering amount: $1.18M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $1 Reported outside-investor minimum
- First sale
- Mar 26, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 9, 2026 | Initial | $1,182,889 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-579658
Series Pre-Seed Preferred Stock and underlying common stock.
Source: Form D, filed Apr 9, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Owen Lozman | Director |
| Alexis Ralli | Director, Executive |
| Blair Robertson | Director |
| Timothy Weaving | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
10 South Hill Park, First Floor Flat
London, X0, NW3 2SB
London, X0, NW3 2SB